Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
SGLT2 inhibitors, such as empagliflozin and canagliflozin, have similar A1C-lowering properties (0.5%-0.8%) and out-of-pocket costs (except for alogliptin, which is available generically), but have the added advantages of CV risk reduction, BP-lowering, and weight loss
Personalized B Complex Solutions at MedHealth360
doi: 10.3389/fphar.2025.1551843 Received 26 December 2024 Accepted 09 June 2025 Published 02 July 2025 Volume 16 - 2025 Edited by Ting Shen, Yangzhou University, China Reviewed by Shuo Yuan, University of Virginia, United States Yan Hu, Second Affiliated Hospital of Dalian Medical University, China Updates Copyright 2025 Mao, Huang, Li, Sun, Zhang, Cheng, Zeng, Lei, Wang and Yao
Journal of Managed Care Pharmacy
US$ 24.50
US$ 28.22
US$ 25.41
US$ 26.05
